Cargando…

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

BACKGROUND: Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse setbacks resulting from the COVID-19 pandemic. We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in se...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Rebecca A, Mukandavire, Christinah, Portnoy, Allison, Weerasuriya, Chathika K, Deol, Arminder, Scarponi, Danny, Iskauskas, Andrew, Bakker, Roel, Quaife, Matthew, Malhotra, Shelly, Gebreselassie, Nebiat, Zignol, Matteo, Hutubessy, Raymond C W, Giersing, Birgitte, Jit, Mark, Harris, Rebecca C, Menzies, Nicolas A, White, Richard G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030455/
https://www.ncbi.nlm.nih.gov/pubmed/36925175
http://dx.doi.org/10.1016/S2214-109X(23)00045-1
_version_ 1784910377928097792
author Clark, Rebecca A
Mukandavire, Christinah
Portnoy, Allison
Weerasuriya, Chathika K
Deol, Arminder
Scarponi, Danny
Iskauskas, Andrew
Bakker, Roel
Quaife, Matthew
Malhotra, Shelly
Gebreselassie, Nebiat
Zignol, Matteo
Hutubessy, Raymond C W
Giersing, Birgitte
Jit, Mark
Harris, Rebecca C
Menzies, Nicolas A
White, Richard G
author_facet Clark, Rebecca A
Mukandavire, Christinah
Portnoy, Allison
Weerasuriya, Chathika K
Deol, Arminder
Scarponi, Danny
Iskauskas, Andrew
Bakker, Roel
Quaife, Matthew
Malhotra, Shelly
Gebreselassie, Nebiat
Zignol, Matteo
Hutubessy, Raymond C W
Giersing, Birgitte
Jit, Mark
Harris, Rebecca C
Menzies, Nicolas A
White, Richard G
author_sort Clark, Rebecca A
collection PubMed
description BACKGROUND: Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse setbacks resulting from the COVID-19 pandemic. We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios. METHODS: We calibrated a tuberculosis model to 105 LMICs (accounting for 93% of global incidence). Vaccine scenarios were implemented as the base-case (routine vaccination of those aged 9 years and one-off vaccination for those aged 10 years and older, with country-specific introduction between 2028 and 2047, and 5-year scale-up to target coverage); accelerated scale-up similar to the base-case, but with all countries introducing vaccines in 2025, with instant scale-up; and routine-only (similar to the base-case, but including routine vaccination only). Vaccines were assumed to protect against disease for 10 years, with 50% efficacy. FINDINGS: The base-case scenario would prevent 44·0 million (95% uncertainty range 37·2–51·6) tuberculosis cases and 5·0 million (4·6–5·4) tuberculosis deaths before 2050, compared with equivalent estimates of cases and deaths that would be predicted to occur before 2050 with no new vaccine introduction (the baseline scenario). The accelerated scale-up scenario would prevent 65·5 million (55·6–76·0) cases and 7·9 million (7·3–8·5) deaths before 2050, relative to baseline. The routine-only scenario would prevent 8·8 million (95% uncertainty range 7·6–10·1) cases and 1·1 million (0·9–1·2) deaths before 2050, relative to baseline. INTERPRETATION: Our results suggest novel tuberculosis vaccines could have substantial impact, which will vary depending on delivery strategy. Including a one-off vaccination campaign will be crucial for rapid impact. Accelerated introduction—at a pace similar to that seen for COVID-19 vaccines—would increase the number of lives saved before 2050 by around 60%. Investment is required to support vaccine development, manufacturing, prompt introduction, and scale-up. FUNDING: WHO (2020/985800-0). TRANSLATIONS: For the French, Spanish, Italian and Dutch translations of the abstract see Supplementary Materials section.
format Online
Article
Text
id pubmed-10030455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd
record_format MEDLINE/PubMed
spelling pubmed-100304552023-03-23 The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study Clark, Rebecca A Mukandavire, Christinah Portnoy, Allison Weerasuriya, Chathika K Deol, Arminder Scarponi, Danny Iskauskas, Andrew Bakker, Roel Quaife, Matthew Malhotra, Shelly Gebreselassie, Nebiat Zignol, Matteo Hutubessy, Raymond C W Giersing, Birgitte Jit, Mark Harris, Rebecca C Menzies, Nicolas A White, Richard G Lancet Glob Health Articles BACKGROUND: Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse setbacks resulting from the COVID-19 pandemic. We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios. METHODS: We calibrated a tuberculosis model to 105 LMICs (accounting for 93% of global incidence). Vaccine scenarios were implemented as the base-case (routine vaccination of those aged 9 years and one-off vaccination for those aged 10 years and older, with country-specific introduction between 2028 and 2047, and 5-year scale-up to target coverage); accelerated scale-up similar to the base-case, but with all countries introducing vaccines in 2025, with instant scale-up; and routine-only (similar to the base-case, but including routine vaccination only). Vaccines were assumed to protect against disease for 10 years, with 50% efficacy. FINDINGS: The base-case scenario would prevent 44·0 million (95% uncertainty range 37·2–51·6) tuberculosis cases and 5·0 million (4·6–5·4) tuberculosis deaths before 2050, compared with equivalent estimates of cases and deaths that would be predicted to occur before 2050 with no new vaccine introduction (the baseline scenario). The accelerated scale-up scenario would prevent 65·5 million (55·6–76·0) cases and 7·9 million (7·3–8·5) deaths before 2050, relative to baseline. The routine-only scenario would prevent 8·8 million (95% uncertainty range 7·6–10·1) cases and 1·1 million (0·9–1·2) deaths before 2050, relative to baseline. INTERPRETATION: Our results suggest novel tuberculosis vaccines could have substantial impact, which will vary depending on delivery strategy. Including a one-off vaccination campaign will be crucial for rapid impact. Accelerated introduction—at a pace similar to that seen for COVID-19 vaccines—would increase the number of lives saved before 2050 by around 60%. Investment is required to support vaccine development, manufacturing, prompt introduction, and scale-up. FUNDING: WHO (2020/985800-0). TRANSLATIONS: For the French, Spanish, Italian and Dutch translations of the abstract see Supplementary Materials section. Elsevier Ltd 2023-03-14 /pmc/articles/PMC10030455/ /pubmed/36925175 http://dx.doi.org/10.1016/S2214-109X(23)00045-1 Text en © 2023 World Health Organization https://creativecommons.org/licenses/by/3.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Articles
Clark, Rebecca A
Mukandavire, Christinah
Portnoy, Allison
Weerasuriya, Chathika K
Deol, Arminder
Scarponi, Danny
Iskauskas, Andrew
Bakker, Roel
Quaife, Matthew
Malhotra, Shelly
Gebreselassie, Nebiat
Zignol, Matteo
Hutubessy, Raymond C W
Giersing, Birgitte
Jit, Mark
Harris, Rebecca C
Menzies, Nicolas A
White, Richard G
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title_full The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title_fullStr The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title_full_unstemmed The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title_short The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
title_sort impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030455/
https://www.ncbi.nlm.nih.gov/pubmed/36925175
http://dx.doi.org/10.1016/S2214-109X(23)00045-1
work_keys_str_mv AT clarkrebeccaa theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT mukandavirechristinah theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT portnoyallison theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT weerasuriyachathikak theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT deolarminder theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT scarponidanny theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT iskauskasandrew theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT bakkerroel theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT quaifematthew theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT malhotrashelly theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT gebreselassienebiat theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT zignolmatteo theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT hutubessyraymondcw theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT giersingbirgitte theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT jitmark theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT harrisrebeccac theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT menziesnicolasa theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT whiterichardg theimpactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT clarkrebeccaa impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT mukandavirechristinah impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT portnoyallison impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT weerasuriyachathikak impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT deolarminder impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT scarponidanny impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT iskauskasandrew impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT bakkerroel impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT quaifematthew impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT malhotrashelly impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT gebreselassienebiat impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT zignolmatteo impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT hutubessyraymondcw impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT giersingbirgitte impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT jitmark impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT harrisrebeccac impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT menziesnicolasa impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy
AT whiterichardg impactofalternativedeliverystrategiesfornoveltuberculosisvaccinesinlowincomeandmiddleincomecountriesamodellingstudy